Online patient and caregiver conversations focused on neuroendocrine neoplasms (NENs): A global thematic analysis. 645Background: NENs are a heterogeneous group of malignancies with complex care needs. Patients and caregivers increasingly use social media to share experiences, exchange information, and seek suppor...

Online patient and caregiver conversations focused on neuroendocrine neoplasms (NENs): A global thematic analysis was published at #GI26 #ASCOGI
ascopubs.org/doi/10.1200/...
Loved collaborating with @ugrewalmd.bsky.social on this one

ASCO Gastrointestinal Cancers Symposium 2026 A prespecified interim analysis of HERIZON-GEA-01 indicates that zanidatamab—a dual HER2-targeted monoclonal antibody that crosslinks neighbouring HER2 receptors and causes receptor clustering—might b...

News - ASCO Gastrointestinal Cancers Symposium 2026

www.thelancet.com/journals/lan...

#GI26 #ASCOGI #GastroSky #OncSky #MedSky

25 Posts Not To Miss From ASCO GI 2026, part 2 - OncoDaily 25 Posts Not To Miss From ASCO GI 2026, part 2 / Amol Akhade, Andreana N. Holowatyj, Arndt Vogel, ASCO, ASCO GI, Azza Sarfraz, Bassam Sonbol, Cathy Eng,

25 Posts Not To Miss From ASCO GI 2026, part 2

oncodaily.com/not-to-miss/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ASCOGI #ASCOGI26 #GI26

Los resultados del estudio BREAKWATER (@skopetz.bsky.social y Josep Tabernero) destacan una posible nueva estrategia terapéutica para pacientes con #CáncerColorrectal metastásico con mutación BRAF V600E.
➡️ https://linke.to/BREAKWATER_Cast
@ascocancer.bsky.social@mdanderson.bsky.social #ASCOGI

Presented at #ASCOGI results from the BREAKWATER study, co-led by @skopetz.bsky.social and Josep Tabernero, a potential new first-line treatment strategy for patients with BRAF V600E–mutant metastatic colorectal cancer.
➡️ https://linke.to/BREAKWATER_Eng
@ascocancer.bsky.social@mdanderson.bsky.social

🌏 High GEA burden in Asia highlights broad patient impact; results to be shared as a late-breaking oral presentation at ASCO GI 2026.

🔗 Read more: bit.ly/ONCOnews07J-05

#ONCOnews #OncoAlert #OncEd #ASCOGI #GastricCancer #Oncology

🔗 Read more: bit.ly/ONCOnews06J-06

#ONCOnews #OncoAlert #OncEd #ColorectalCancer #CancerResearch #CancerPrevention #ASCOGI

🌍 The program effectively reached younger patients, those with advanced disease, with plans to scale and further evaluate outcomes.

🔗 Read more: bit.ly/ONCOnews06J-05

#ONCOnews #OncoAlert #OncEd #ColorectalCancer #CancerResearch #ASCOGI

📈 Early-onset CRC is rising globally, now accounting for ~10% of cases and often presenting as advanced, left-sided disease.

🔗 Read more: bit.ly/ONCOnews06J-04

#ONCOnews #OncoAlert #OncEd #ColorectalCancer #CancerResearch #ASCOGI

🔄 HER2 status may change over time in advanced upper GI cancers, with loss of overexpression frequently observed, highlighting the potential value of repeat testing in selected patients.

🔗 Read more: bit.ly/ONCOnews06J-03

#ONCOnews #OncoAlert #OncEd #PrecisionMedicine #Biomarkers #ASCOGI

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer - OncoDaily Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer / ASCO GI, Bevacizumab, BRAF

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
@skopetz.bsky.social
@fda.gov

oncodaily.com/insight/meta...

#ASCOGI #Bevacizumab #Cancer #ColorectalCancer #EncorafenibCetiximab #FDA #OncoDaily #Oncology #Pfizer #CRC

Cizzle Bio representatives with the Debbie’s Dream Foundation team at the 2025 ASCO GI Symposium, standing in front of the foundation’s booth, which is dedicated to raising awareness, funding research, and supporting patients with stomach cancer. The event highlights collaborations in early cancer detection and advancements in gastrointestinal oncology.

Connected with Debbie's Dream Foundation at #ASCOGI! Their work in raising awareness & funding for stomach cancer research is truly inspiring. Advocacy groups like these are vital in the fight against cancer. 💙 Thank you for all you do! #medsky #cansky #oncsky #cancer #cancerresearch #oncology

Patients with colon cancer with positive ctDNA tests often face tougher outcomes. Research by @danafarber.bsky.social & Brigham and Women’s Hospital presented at #ASCOGI shows that treatment with a non-steroidal anti-inflammatory drug significantly boosts disease-free survival. bit.ly/4g9zO01

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - Nature Medicine As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF inhibitor encorafenib,...

New out in #NatureMedicine & at #ASCOGI: In the practice-changing #BREAKWATER ph3 trial, encorafenib, cetuximab & mFOLFOX6 vs investigator’s choice of CT w/wo bev in BRAF V600E mCRC led to improved ORR, w/ PFS still maturing.
Congrats to @skopetz.bsky.social et al!
www.nature.com/articles/s41...

Daraxonrasib looks a bit more efficacious but zoldonrasib's safety profile is remarkable. MTD wasn't reached but it seems to be maxing out on exposure

#ASCOGI

Efficacy of pan-RAS and KRAS G12D inhibitors from $RVMD in 2L PDAC: 36% and 30% ORR for daraxonrasib and zoldonrasib, respectively

#ASCOGI

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

www.thelancet.com/journals/lan...

@thelancet.bsky.social

#GastroSky #MedSky #ASCOGI #OncSky @oncoalert.bsky.social

Pamrevlumab Plus Chemo Fails to Improve Survival in Unresectable Locally Advanced Pancreatic Cancer Pamrevlumab plus chemotherapy failed to demonstrate a survival benefit in patients with locally advanced, unresectable pancreatic cancer.

Pamrevlumab Plus Chemo Fails to Improve Survival in Unresectable Locally Advanced Pancreatic Cancer #GI25 #ASCOGI #oncology

www.onclive.com/view/pamrevl...

Surufatinib Plus TAS-102 Displays Activity, Safety in Later-Line Metastatic PDAC Surufatinib with TAS-102 produced promising survival outcomes and manageable toxicity as later-line therapy for a small cohort of patients with PDAC.

Surufatinib Plus TAS-102 Displays Activity, Safety in Later-Line Metastatic PDAC @ASCO
#GI25 #ASCOGI #oncology

www.onclive.com/view/surufat...

ASCOGI 2025

🔴 Eduardo Terán, from VHIO's Upper Gastrointestinal & Endocrine Tumor Group, presented the poster "Molecular profiling of a gastroesophageal adenocarcinoma multicohort using next-generation sequencing" at #ASCOGI. 🩺🔬

Addition of Camrelizumab and Rivoceranib to TACE Boosts PFS in Unresectable HCC TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.

Addition of Camrelizumab and Rivoceranib to TACE Boosts PFS in Unresectable HCC
#ASCOGI #oncology

www.onclive.com/view/additio...

Gastrointestinal Cancers Symposium | ASCO Daily News The latest scientific coverage and expert insights from the ASCO Gastrointestinal Cancers Symposium, all in one place.

The preview issue of #ASCODailyNews for #ASCOGI is now out and includes a planning guide, an interview with Keynote lecturer @pamelakunzmd.bsky.social, and session previews. dailynews.ascopubs.org/meetings/gas...
@ascocancer.bsky.social